

BCL2/IGH in Healthy Individuals (Limpens et al. 1991; Roulland et al. 2006)

- BCL2/IGH is found in peripheral blood of up to 70% of normal adults over age 50
 - Numbers increase with age
 - Numbers increase with pesticide use in farmers
- BCL2/IGH + B-cells are <u>not</u> naïve B-cells
 - Memory B-cells, Class switched
 - Have encountered the germinal center reaction
 - Prone to intense trafficking among germinal centers
- Rare cases of FLIS & FL-like B-cells in same pt (Cheung et al. Leukemia 2009)

FLIS is most often an isolated event in a reactive LN Very low risk of FL if not detected at initial staging (3%) May be incidental finding with other B-cell lymphomas (15%)




Composite FL in situ with Nodal MZL (5 cases composite with another B-cell lymphoma)



FLIS in association with B-cell lymphomas

- A "FLIS-like" lesion can be detected in patients with known FL, either preceding diagnosis, at diagnosis, or at relapse
 - Should be considered a form of dissemination (17%; Jegalian et al)
- FLIS is often an incidental finding in patients with another B-cell lymphoma
 - 15-30 % Jegalian, Montes-Moreno, Pillai
 - CLL, CHL, SMZL, NMZL, LPL, DLBCL
- May suggest genomic instability, inc risk



Why do FLIS lymph nodes get biopsied? •Usually an incidental finding

- 2.3% of unselected LN, Hennopp et al. 2011 (~1300 biopsies)
•Unrelated immune stimulus may lead to increased trafficking of FL-like B-cells to germinal centers

- FLIS LN's usually show reactive hyperplasia

HCV infection assoc with expansion of PB t(14;18) +

- Numbers decrease with treatment of HCV

In Situ FL vs. Partial Involvement


<u>In situ FL</u>


- Architecture intact
- Follicle size normal
- Involved follicles widely scattered
- Intact mantle cuff with sharp edge to GC
- Very strong BCL2 and CD10 expression
- Almost pure centrocytes


Partial FL

- Altered architecture
- Follicle size often expanded
- Involved follicles close together, adjacent
- Blurred edge to GC attenuated mantle cuff
- BCL2 and CD10 not as strong and more variable
- Cytology more varied, CB/ CC










What are the genetic differences between FLIS and Follicular Lymphoma Bonzheim et al. Blood 2011

- Array CGH to compare FLIS with FL
 - Synchronous FL was negative for BCL2 protein
 - Point mutation found in BCL2 gene
- Other genetic changes acquired in FL
 - Gains n 6p22.2
 - Losses in 6q14.1
 - FISH confirmed 6q loss in FL

Microdissection of RH, FLIS, PFL, iFL & FL


FLIS





iFL


Array CGH: Number of major alterations per sample Mamessier E et al.



Number of gains and losses in early-FL and FL samples (>700kb)

Gain

Loss




Conclusions

E. Mamessier, J. Song, S. Roulland, A. Chott, E. Jaffe, B. Nadel

- Array CGH data show a stepwise increase in chromosomal aberrations in FLIS, FL with partial involvement, duodenal FL, FL Grade 1-2, and FL Grade 3A
- Most of the affected regions in FLIS are the same as those altered in usual FL
- The specific genetic alterations that lead to progression are yet to be elucidated

What is the obligation of the pathologist to detect this and other in situ lesions?

- At present, no treatment is recommended for FLIS or other in situ lesions
- BCL2 and CyclinD1 immunohistochemistry need not be done on every reactive lymph node biopsy
- One can anticipate finding these in situ lesions in reactive lymph nodes without atypical features



- FL-like B-cells home to the germinal center environment
- Lack of progression in most patients suggests BCL2/IGH is necessary but not sufficient for neoplastic transformation

-Second hit is required

 FL-like PB B-cells & FL in situ are different phases of the same incipient neoplasia

Terminology: Follicular lymphoma in situ (FLIS) FL-like B-cells of Uncertain Significance (FLBUS)